Volkswagen announces departure of Gunnar Kilian from management board

Gunnar Kilian Member of the Board of Management of Volkswagen AG
Gunnar Kilian Member of the Board of Management of Volkswagen AG
0Comments

Gunnar Kilian has departed from Volkswagen AG’s Group Board of Management, where he held responsibility for Human Resources. His duties will be temporarily assumed by Thomas Schäfer. This decision was made by the Group Supervisory Board due to differing opinions on the management of holding companies.

Chairman of the Supervisory Board Hans Dieter Pötsch and Chairman of the Board of Management Oliver Blume acknowledged Kilian’s contributions. Pötsch stated, “Gunnar Kilian has been instrumental in the Group’s transformation in recent years. He ensured that the Human Resources Division is fit for the future and played a key role in the strategic realignment of the commercial vehicle business.” Blume added, “Gunnar Kilian used his in-depth knowledge of the Group and its structures to set important factors in motion that will shape the Group’s long-term success.”



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.